Xeris Biopharma Holdings

XeriSol glucagon (internal code 17225) is a small-molecule glucagon formulation developed by Xeris Biopharma Holdings for Type 1 diabetes management. The program is based on glucagon hydrochloride, a well-established hormone therapeutic available under the brand GLUCAGEN HYPOKIT, administered via intramuscular, intravenous, or subcutaneous routes. The Phase 1 trial (NCT03424044) was completed as of May 27, 2020, representing the most recent disclosed milestone. Glucagon hydrochloride is already approved in both the United States and Australia, with multiple manufacturers including Novo Nordisk, Lilly, Fresenius Kabi, and Quad Pharmaceuticals holding regulatory approvals. Xeris's development strategy appears focused on optimizing glucagon delivery or formulation for diabetes indications. The current development status indicates Phase 1 completion, though subsequent milestones and regulatory pathways have not been publicly disclosed. The competitive landscape includes emerging monoclonal antibody approaches such as Sana Biotechnology's UP421, currently in Phase 1 development.

Type 1 diabetes affects millions globally and requires reliable acute treatment for hypoglycemic episodes, a potentially life-threatening complication of insulin therapy. Glucagon is the standard-of-care emergency treatment for severe hypoglycemia, but existing formulations face limitations including reconstitution requirements, storage stability, and user complexity that can delay treatment in critical situations. Xeris's development of an optimized glucagon formulation addresses the unmet need for faster, more reliable, and easier-to-administer rescue therapies. The market for glucagon and glucagon-like therapies is substantial, driven by the large Type 1 diabetes population and the universal need for hypoglycemia rescue medications. Regulatory approval of improved glucagon formulations can capture significant market share from incumbent products. The competitive emergence of alternative mechanisms, such as monoclonal antibodies targeting glucagon signaling pathways, suggests industry recognition of the commercial and clinical importance of this therapeutic area. Successful development could establish Xeris as a key player in diabetes emergency care, with potential for label expansion to Type 2 diabetes and other hyperinsulinemic conditions.

Drug Class: Glucagon, a peptide hormone agonist at the glucagon receptor.

Modality: Small molecule (per program classification).

Active Ingredient: Glucagon hydrochloride.

Brand Name: GLUCAGEN HYPOKIT.

Routes of Administration: Intramuscular, intravenous, and subcutaneous injection.

Mechanism of Action: Not yet disclosed for this specific formulation; glucagon classically acts as a G-protein coupled receptor agonist to stimulate hepatic glucose production and reverse hypoglycemia.

Target: Not yet disclosed.

Related Therapies: Existing glucagon products (Novo Nordisk, Lilly, Fresenius Kabi, Quad Pharmaceuticals); emerging monoclonal antibody approaches such as UP421 (Sana Biotechnology).

Regulatory History: Glucagon hydrochloride has been approved in Australia since 1991 (PBS codes 1449G, 3467L, 5105Q) and in the United States under multiple NDAs and ANDAs.

Patent Status: Not yet disclosed.

United States: Glucagon hydrochloride is approved by the FDA under multiple applications (NDA012122, NDA020918, NDA201849, ANDA071022, ANDA071023) held by Novo Nordisk, Lilly, Fresenius Kabi, and Quad Pharmaceuticals. Regulatory pathway and approval status for the XeriSol formulation specifically have not been disclosed.

Australia: Glucagon hydrochloride is approved by the Therapeutic Goods Administration (TGA) and listed on the Australian Register of Therapeutic Goods (ARTG) under PBS codes 1449G, 3467L, and 5105Q, with first listings dating to August 1, 1991 and December 1, 1994. Sponsor: Novo Nordisk Pharmaceuticals Pty. Limited.

European Medicines Agency (EMA): Regulatory status not yet disclosed.

Japan (PMDA): Regulatory status not yet disclosed.

China (NMPA): Regulatory status not yet disclosed.

The XeriSol glucagon program has not yet filed for regulatory approval; next regulatory milestones are not yet disclosed.

Strategic Implications: Xeris's Phase 1 completion of XeriSol glucagon in May 2020 represents progress toward a potential differentiated glucagon formulation for Type 1 diabetes. The absence of disclosed milestones since May 2020 suggests either a pause in development, delayed publication of results, or transition to later-stage trials not yet announced. The small-molecule classification is notable given that glucagon is a peptide hormone, potentially indicating a novel chemical entity or reformulation approach.

Competitive Implications: Xeris enters a market dominated by established manufacturers with approved products and strong market positions. Differentiation through improved formulation, faster onset, improved stability, or simplified administration will be essential to justify development investment and capture market share. The emergence of alternative mechanisms (e.g., Sana's monoclonal antibody UP421) suggests industry exploration of novel glucagon signaling approaches, though these remain early-stage.

Future Catalysts: Publication of Phase 1 results; initiation of Phase 2 trials; regulatory interactions with FDA or other authorities; potential partnerships or licensing agreements; clinical data on efficacy, safety, and user experience compared to incumbent products.

Expected Milestones: Next regulatory or clinical milestone dates are not yet disclosed. Typical development timelines would suggest Phase 2 initiation within 1–2 years of Phase 1 completion, though no such announcement has been made as of the latest available data.